Lensar (LNSR) Net Income towards Common Stockholders (2019 - 2026)
Lensar's (LNSR) quarterly Net Income towards Common Stockholders came in at $2.1 million in Q2 2026, up 220.98% year-over-year from $664849.2 in Q2 2025, and down 88.72% quarter-over-quarter from $18.9 million in Q1 2026.
Analysis
Lensar (LNSR) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Lensar (LNSR) has reported Net Income towards Common Stockholders for 8 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 220.98% year-over-year to $2.1 million in Q2 2026; TTM through Jun 2026 was $15.9 million, a 132.2% increase from a year earlier, with the FY2025 full-year figure at -$34.3 million, down 9.16% from the prior year.
- Net Income towards Common Stockholders was $2.1 million for Q2 2026 at Lensar, down from $18.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $18.9 million in Q1 2026 and troughed at -$27.3 million in Q1 2025.
- A 5-year average of -$4.4 million and a median of -$3.8 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders tumbled 1167.73% in 2025 and surged 220.98% in 2026, its largest moves.
- Over 5 years, Net Income towards Common Stockholders stood at -$2.5 million in 2022, then slumped by 57.67% to -$3.9 million in 2023, then slumped by 376.36% to -$18.7 million in 2024, then soared by 92.2% to -$1.5 million in 2025, then soared by 246.36% to $2.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $2.1 million (Q2 2026), $18.9 million (Q1 2026), and -$1.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.42 Bn | 178.82 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 124.16 Bn | 118.94 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 118.41 Bn | 109.59 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 104.45 Bn | 100.98 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.47 Bn | 65.93 Bn | 3.85 Bn | 907.00 Mn |
| 6 | Edwards Lifesciences | 49.71 Bn | 45.46 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.95 Bn | 32.50 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.24 Bn | 30.29 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.17 Bn | 20.68 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Lensar | 103.29 Mn | 89.73 Mn | 9.78 Mn | 2.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.13 Mn |
| Mar 31, 2026 | 18.91 Mn |
| Dec 31, 2025 | -1.46 Mn |
| Sep 30, 2025 | -3.71 Mn |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | -27.35 Mn |
| Dec 31, 2024 | -18.70 Mn |
| Sep 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -9.04 Mn |
| Mar 31, 2024 | -2.16 Mn |
| Dec 31, 2023 | -3.93 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | -8.75 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -2.49 Mn |
| Sep 30, 2022 | -3.99 Mn |
| Jun 30, 2022 | -6.76 Mn |
| Mar 31, 2022 | -6.67 Mn |
| Dec 31, 2021 | -3.90 Mn |
| Sep 30, 2021 | -6.16 Mn |